The first Article 13 claim based on newly developed evidence or proprietary data [a special category under Article 13(5)] to be achieved, in December 2009, was for Fruitflow , when the EU Commission authorized the health claim “watersoluble tomato concentrate (WSTC) I and II helps maintain normal platelet aggregation, which contributes to healthy blood flow”. The authorized claim was based on the eight human studies (seven proprietary), and seven nonhuman studies (three proprietary), conducted with Fruitflow , which is given in Table 5.
So we got EFSA approval on healthy blood flow based on 15 studies. I don't think for one moment that we needed all fifteen, but I also doubt two or three small scale studies would have got us that approval.
We know we're nearing the end of our second small study, and it may well be that other studies done by Duttaroy could be used as supporting evidence, but my gut reaction is that we'll need more evidence before we can try going for a BP claim. What we won't want to do is spend a lot of time on going for a claim unless we're pretty sure we'll get a positive outcome.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.